D89.81
Graft-versus-host disease
Clinical Classification Guidelines
Use Additional Code
- code to identify associated manifestations, such as:
- desquamative dermatitis (L30.8)
- diarrhea (R19.7)
- elevated bilirubin (R17)
- hair loss (L65.9)
Code First
- underlying cause, such as:
- complications of transplanted organs and tissue (T86.-)
- complications of blood transfusion (T80.89)
Medical Intelligence & Overview
Graft-versus-host disease (GVHD) is a medical condition that can occur after a person receives a bone marrow or stem cell transplant. In GVHD, the transplanted donor cells attack the recipient's tissues, leading to inflammation and damage. Although it can be a serious complication, advances in medical treatments have improved the outlook for many affected individuals. Recognizing the causes, symptoms, diagnosis, and treatment options is essential for managing this condition effectively.
Causes & Symptoms
Clinical Causes: Receiving a bone marrow, stem cell, or organ transplant from a donor. Mismatch between donor and recipient tissue types, especially human leukocyte antigen (HLA) incompatibility. Presence of certain immune cells in the transplanted tissue that target the recipient's tissues. Early onset after transplant, typically within the first few months. Certain factors like age, pre-existing conditions, or immune suppression may influence the risk.
Key Symptoms: Skin rashes or dermatitis, often starting on the palms or soles. Liver problems, such as jaundice or elevated liver enzymes. Gastrointestinal issues including nausea, vomiting, diarrhea, or abdominal pain. Dry eyes or mouth due to mucosal involvement. Weight loss and fatigue. Fever and chills without infection.
Diagnostic & Treatment
Diagnosis Path: Diagnosis of graft-versus-host disease involves a combination of clinical evaluation, medical history, and laboratory tests. Healthcare providers may perform skin biopsies, liver function tests, or endoscopic examinations of the gastrointestinal tract. Imaging studies can help assess organ involvement. No single test definitively confirms GVHD, so diagnosis relies on characteristic clinical features and laboratory findings.
Treatment Protocols: Immunosuppressive medications such as corticosteroids, calcineurin inhibitors, or methotrexate. Photopheresis or other targeted therapies to modulate immune activity. Supportive care, including wound care, nutritional support, and treatment of infections. Monitoring and managing organ-specific complications. In some cases, additional therapies like cell therapy or biologic agents may be considered.
Clinical Advice & FAQs
Billing Guidance
Is D89.81 a billable ICD-10 code?
Yes, D89.81 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D89.81?
Clinical documentation must specify the nature of Graft-versus-host disease and any associated comorbidities for accurate reporting.
Cite this Clinical Reference